177Lu-BetaBart in Patients With Relapsed/Refractory, Locally Advanced Inoperable, or Metastatic Solid Tumors
Castration-Resistant Prostate Cancer (CRPC) · Colorectal Cancer · NSCLC (Non-small Cell Lung Cancer) · Ovarian Cancer · Cervical Cancer · Endometrial Cancer · TNBC, Triple Negative Breast Cancer · Small Cell Lung Cancer (SCLC ) · Head &Amp; Neck Squamous Cell Carcinoma (HNSCC) · Esophageal Squamous Cell Carcinoma (ESCC) · Sarcoma
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
No warning signs right now. That's why the score is 0.
Score over time
- Stage
- Phase 1/2
- Patients
- 61 (planned)
- Started
- Feb 23, 2026
- Main results expected
- Dec 2027
- Fully finished
- Dec 2027
- Results posted
- not yet
What counts as success
The trial's main goal(s), called the “primary outcome.”
Safety and Tolerability of 177LuBetaBart
Measured over: 6 weeks
To assess the preliminary anti-tumor activity of 177Lu-BetaBart at the RP2D
Measured over: Up to 30 weeks
To assess preliminary anti-tumor activity, as defined by biochemical response, in CRPC participants at the RP2D
Measured over: Up to 30 weeks
Changes Tremor has spotted
Show details (technical version)
Score inputs
- none
Raw record changes
- none yet
Trial ID NCT07189871 · record last updated 2026-10-01 · checked 2026-11-09 15:47 UTC